New Data from Sagimet’s Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640’s Positive Effect Across Patients with NASH in the U.S. and China

SAN MATEO, Calif.: SAN MATEO, Calif., Nov. 12, 2021 /PRNewswire/ -- Sagimet Biosciences, a clinical-stage biotechnology company, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will give an oral presentation on consolidated results from the Phase 2 FASCINATE-1 trial of Sagimet's lead...

Click to view original post